– USA, MA – Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced the appointment of Abbie Celniker, Ph.D., to its Board of Directors.
“Abbie brings nearly three decades of business and scientific leadership in the biotechnology and pharmaceutical industries to Dyax, with a proven track record of successfully developing and commercializing life science products,” said Henry E. Blair, Chairman of Dyax’s Board of Directors. “Her expertise in advancing late-stage protein therapeutic discovery and development programs will provide the Board with a new and valued perspective as we develop DX-2930 and build our internal pipeline. We are delighted to welcome her to Dyax’s Board.”
“I look forward to working alongside the Board and management team to help Dyax develop and expand its internal pipeline,” commented Dr. Celniker.
Dr. Celniker currently serves as the President and Chief Executive Officer of Eleven Biotherapeutics, where she also serves on its Board of Directors. Prior to joining Eleven Biotherapeutics, she served as the Executive Vice President, Translational Medicine of Alexion Pharmaceuticals, Inc. From 2008 to 2011, Dr. Celniker served as the President and Chief Executive Officer and as a member of the Board of Directors of Taligen Therapeutics, Inc. which was ultimately acquired by Alexion Pharmaceuticals. Previously, Dr. Celniker served as Global Head of Biologics at Novartis AG, Senior Vice President of Research and Development Strategy and Operations at Millennium Pharmaceuticals, Inc. and as Vice President Protein Technologies at the Wyeth Research facilities in Cambridge, Massachusetts.
Dr. Celniker has served as Chair of ImaginAb, a privately held biotechnology company and is currently Vice Chair of MassBio, a not for profit trade organization for biotechnology in the Commonwealth of Massachusetts. Dr. Celniker holds a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of Arizona.
About Dyax
Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of hereditary angioedema (HAE) attacks. In March 2015, the Company reported positive safety, pharmacokinetic, biomarker and proof-of-concept efficacy results from itsPhase 1b clinical trial of DX-2930 in HAE patients. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.
Both DX-2930 and KALBITOR were identified using Dyax’s proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes one FDA approved product, Eli Lilly and Company’s CYRAMZA® (ramucirumab), for which Dyax receives royalties, and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and/or royalties.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
